4//SEC Filing
Gelbfish Gary A. 4
Accession 0001654954-17-011653
CIK 0001410098other
Filed
Dec 13, 7:00 PM ET
Accepted
Dec 14, 4:12 PM ET
Size
12.9 KB
Accession
0001654954-17-011653
Insider Transaction Report
Form 4
CorMedix Inc.CRMD
Gelbfish Gary A.
Director
Transactions
- Purchase
Common Stock, $0.001 par value per share
2017-12-12$0.48/sh+52,083$25,000→ 2,101,121 total
Holdings
- 50,000
Series C-3 Non-Voting Convertible Preferred Stock
From: 2014-01-08→ Common Stock, $0.001 par value per share (500,000 underlying) - 250,000
Warrant (Right to Purchase Common Stock)
Exercise: $0.90From: 2015-01-08Exp: 2020-01-08→ Common Stock, $0.001 par value per share (250,000 underlying) - 14,000(indirect: By Foundation)
Common Stock, $0.001 par value per share
- 75,000
Stock Option (Right to Buy Common Stock)
Exercise: $0.37Exp: 2027-08-03→ Common Stock, $0.001 par value per share (75,000 underlying) - 1,000,000
Series A Common Stock Warrant
Exercise: $0.75→ Common Stock, $0.001 par value per share (1,000,000 underlying) - 1,000,000
Series B Common Stock Warrant
Exercise: $1.05→ Common Stock, $0.001 par value per share (1,000,000 underlying)
Footnotes (6)
- [F1]Purchase was contracted on November 17, 2017, but not closed until December 12, 2017.
- [F2]Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
- [F3]These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019.
- [F4]The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual.
- [F5]The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date.
- [F6]The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date.
Documents
Issuer
CorMedix Inc.
CIK 0001410098
Entity typeother
Related Parties
1- filerCIK 0001488011
Filing Metadata
- Form type
- 4
- Filed
- Dec 13, 7:00 PM ET
- Accepted
- Dec 14, 4:12 PM ET
- Size
- 12.9 KB